FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977318507> ?p ?o ?g. }

• W2977318507 endingPage "1618" @default.
• W2977318507 startingPage "1617" @default.
• W2977318507 abstract "The NEJ026 study 1 Saito H Fukuhara T Furuya N et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019; 20: 625-635 Summary Full Text Full Text PDF PubMed Scopus (363) Google Scholar in patients with EGFR-positive non-small-cell lung cancer (NSCLC) showed that the combination of erlotinib (150 mg/day) plus intravenous bevacizumab (15 mg/kg once every 21 days) yields a median progression-free survival of 16·9 months (95% CI 14·2–21·0) compared with 13·3 months (11·1–15·3) in patients treated with erlotinib alone (p=0·016). The trial was permissive, allowing patients with CNS metastases (32% in each group) and an Eastern Cooperative Oncology Group performance status of 2 or lower to enroll. Median progression-free survival was also longer in patients with Leu858Arg mutations in the erlotinib and bevacizumab group (17·4 months [95% CI 12·6–not estimable]) than in the erlotinib group (13·7 months [8·8–15·5]). However, no significant differences were found between treatment groups in patients with EGFR exon 19 deletions. 1 Saito H Fukuhara T Furuya N et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019; 20: 625-635 Summary Full Text Full Text PDF PubMed Scopus (363) Google Scholar In The Lancet Oncology, Kazuhiko Nakagawa and colleagues 2 Nakagawa K Garon EB Seto T et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; (published online Oct 3)https://doi.org/10.1016/S1470-2045(19)30634-5 Summary Full Text Full Text PDF PubMed Scopus (312) Google Scholar report the results of a phase 3 trial (RELAY) assessing the combination of erlotinib 150 mg/day plus ramucirumab (an anti-VEGFR2 antibody) 10 mg/kg intravenously every 2 weeks versus erlotinib 150 mg/day plus intravenous placebo every 2 weeks. Median progression-free survival was 19·4 months (95% CI 15·4–21·6) in the erlotinib plus ramucirumab group versus 12·4 months (11·0 −13·5) in the erlotinib plus placebo group (hazard ratio 0·59 [95% CI 0·46–0·76], p<0·0001). Grade 3 hypertension occurred in 52 (24%) of the 221 patients in the erlotinib plus ramucirumab group safety population. In the previous NEJ026 study, 1 Saito H Fukuhara T Furuya N et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019; 20: 625-635 Summary Full Text Full Text PDF PubMed Scopus (363) Google Scholar in the erlotinib plus bevacizumab group, grade 3 hypertension also occurred in 23% of the patients. Both trials shed light on the convenience of combining EGFR tyrosine kinase inhibitors with other drugs. However, several questions arise, because in both trials, the proportion of patients attaining a complete response was very low in the combination group: three (1%) of 224 in RELAY and eight (7%) of 112 in NEJ026. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialRamucirumab plus erlotinib demonstrated superior progression-free survival compared with placebo plus erlotinib in patients with untreated EGFR-mutated metastatic NSCLC. Safety was consistent with the safety profiles of the individual compounds in advanced lung cancer. The RELAY regimen is a viable new treatment option for the initial treatment of EGFR-mutated metastatic NSCLC. Full-Text PDF" @default.
• W2977318507 created "2019-10-10" @default.
• W2977318507 creator A5017298994 @default.
• W2977318507 creator A5044887899 @default.
• W2977318507 date "2019-12-01" @default.
• W2977318507 modified "2023-09-26" @default.
• W2977318507 title "Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?" @default.
• W2977318507 cites W2033655900 @default.
• W2977318507 cites W2039013742 @default.
• W2977318507 cites W2062967876 @default.
• W2977318507 cites W2163832829 @default.
• W2977318507 cites W2603774629 @default.
• W2977318507 cites W2789478657 @default.
• W2977318507 cites W2887381522 @default.
• W2977318507 cites W2937223370 @default.
• W2977318507 cites W2953798516 @default.
• W2977318507 cites W2978677918 @default.
• W2977318507 doi "https://doi.org/10.1016/s1470-2045(19)30636-9" @default.
• W2977318507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31591061" @default.
• W2977318507 hasPublicationYear "2019" @default.
• W2977318507 type Work @default.
• W2977318507 sameAs 2977318507 @default.
• W2977318507 citedByCount "2" @default.
• W2977318507 countsByYear W29773185072020 @default.
• W2977318507 countsByYear W29773185072022 @default.
• W2977318507 crossrefType "journal-article" @default.
• W2977318507 hasAuthorship W2977318507A5017298994 @default.
• W2977318507 hasAuthorship W2977318507A5044887899 @default.
• W2977318507 hasConcept C121608353 @default.
• W2977318507 hasConcept C126322002 @default.
• W2977318507 hasConcept C143998085 @default.
• W2977318507 hasConcept C168563851 @default.
• W2977318507 hasConcept C2776256026 @default.
• W2977318507 hasConcept C2776694085 @default.
• W2977318507 hasConcept C2777802072 @default.
• W2977318507 hasConcept C2778087573 @default.
• W2977318507 hasConcept C2779438470 @default.
• W2977318507 hasConcept C2909325608 @default.
• W2977318507 hasConcept C61943457 @default.
• W2977318507 hasConcept C71924100 @default.
• W2977318507 hasConcept C90924648 @default.
• W2977318507 hasConceptScore W2977318507C121608353 @default.
• W2977318507 hasConceptScore W2977318507C126322002 @default.
• W2977318507 hasConceptScore W2977318507C143998085 @default.
• W2977318507 hasConceptScore W2977318507C168563851 @default.
• W2977318507 hasConceptScore W2977318507C2776256026 @default.
• W2977318507 hasConceptScore W2977318507C2776694085 @default.
• W2977318507 hasConceptScore W2977318507C2777802072 @default.
• W2977318507 hasConceptScore W2977318507C2778087573 @default.
• W2977318507 hasConceptScore W2977318507C2779438470 @default.
• W2977318507 hasConceptScore W2977318507C2909325608 @default.
• W2977318507 hasConceptScore W2977318507C61943457 @default.
• W2977318507 hasConceptScore W2977318507C71924100 @default.
• W2977318507 hasConceptScore W2977318507C90924648 @default.
• W2977318507 hasIssue "12" @default.
• W2977318507 hasLocation W29773185071 @default.
• W2977318507 hasLocation W29773185072 @default.
• W2977318507 hasOpenAccess W2977318507 @default.
• W2977318507 hasPrimaryLocation W29773185071 @default.
• W2977318507 hasRelatedWork W1667731616 @default.
• W2977318507 hasRelatedWork W2005973176 @default.
• W2977318507 hasRelatedWork W2186047679 @default.
• W2977318507 hasRelatedWork W2341730833 @default.
• W2977318507 hasRelatedWork W2804337541 @default.
• W2977318507 hasRelatedWork W2885601937 @default.
• W2977318507 hasRelatedWork W2906578683 @default.
• W2977318507 hasRelatedWork W2943986043 @default.
• W2977318507 hasRelatedWork W2999270520 @default.
• W2977318507 hasRelatedWork W4382399942 @default.
• W2977318507 hasVolume "20" @default.
• W2977318507 isParatext "false" @default.
• W2977318507 isRetracted "false" @default.
• W2977318507 magId "2977318507" @default.
• W2977318507 workType "article" @default.